Page last updated: 2024-09-05

solifenacin succinate and tadalafil

solifenacin succinate has been researched along with tadalafil in 6 studies

Compound Research Comparison

Studies
(solifenacin succinate)
Trials
(solifenacin succinate)
Recent Studies (post-2010)
(solifenacin succinate)
Studies
(tadalafil)
Trials
(tadalafil)
Recent Studies (post-2010) (tadalafil)
5221943431,7423921,089

Protein Interaction Comparison

ProteinTaxonomysolifenacin succinate (IC50)tadalafil (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0012
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0012
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)3.0704
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaHomo sapiens (human)2.928
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)3.0704
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.5153
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)5.1
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaBos taurus (cattle)4.05
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaHomo sapiens (human)2.928
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Bos taurus (cattle)5.1
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)2.928
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)5.1
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaBos taurus (cattle)5.1
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)9.2
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaHomo sapiens (human)2.928
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)2.507
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)3.0704
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.012
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)4.6028
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)9.2
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)4.6028
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)3.0704
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)2.928
cGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)0.0075
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaBos taurus (cattle)5.1
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)0.8575
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)3.0704
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)3.0704

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Bergamasco, L; Gualà, L; Maselli, G; Pace, G; Silvestri, V; Vicentini, C1
De Nunzio, C; Tubaro, A1
Pannek, J1
Anjiki, H; Hagiwara, K; Hayashida, M; Kurosawa, K; Nagamoto, S; Ogawa, K; Oka, S; Okaneya, T; Sakaguchi, K; Urakami, S; Yano, A1
Eisner, BH; Hinojosa-Gonzalez, DE; Segall, MR1
Azis, A; Ciayadi, TA; Hendarto, J; Kholis, K; Palinrungi, MA; Syahrir, S; Syarif, S1

Reviews

3 review(s) available for solifenacin succinate and tadalafil

ArticleYear
Benign prostatic hyperplasia in 2014: Innovations in medical and surgical treatment.
    Nature reviews. Urology, 2015, Volume: 12, Issue:2

    Topics: Acetylcholine Release Inhibitors; Botulinum Toxins, Type A; Drug Combinations; Humans; Laser Therapy; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Solifenacin Succinate; Sulfonamides; Tadalafil; Tamsulosin; Transurethral Resection of Prostate; Urological Agents

2015
[Overactive bladder-which treatment when?]
    Der Urologe. Ausg. A, 2017, Volume: 56, Issue:12

    Topics: Behavior Therapy; Botulinum Toxins, Type A; Diagnosis, Differential; Electric Stimulation Therapy; Female; Gabapentin; Humans; Injections, Intramuscular; Lumbosacral Plexus; Male; Muscarinic Antagonists; Patient Preference; Physical Therapy Modalities; Solifenacin Succinate; Tadalafil; Urinary Bladder; Urinary Bladder, Overactive

2017
Pharmacological Management of Ureteral Stent-related Symptoms: A Systematic Review, Bayesian Network Meta-analysis, and Meta-regression.
    The Journal of urology, 2023, Volume: 210, Issue:5

    Topics: Bayes Theorem; Cholinergic Antagonists; Humans; Network Meta-Analysis; Pain; Prospective Studies; Quality of Life; Solifenacin Succinate; Stents; Tadalafil; Ureter

2023

Trials

3 trial(s) available for solifenacin succinate and tadalafil

ArticleYear
Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study.
    International journal of urology : official journal of the Japanese Urological Association, 2011, Volume: 18, Issue:7

    Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Surveys and Questionnaires; Tadalafil; Tetrahydroisoquinolines; Therapeutics; Urination Disorders; Urodynamics

2011
Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α
    Lower urinary tract symptoms, 2019, Volume: 11, Issue:3

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Pilot Projects; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Solifenacin Succinate; Tadalafil; Urological Agents

2019
A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms.
    The Pan African medical journal, 2023, Volume: 46

    Topics: Humans; Pain; Quality of Life; Solifenacin Succinate; Stents; Tadalafil; Urological Agents

2023